Skip to content

Released Nov 5, 2019, after the close

10-Q filed Nov 5, 2019, 36 days after period end · 0001564590-19-040360

Q3 2019 · 10-Q
Revenue$2.43M+136.7% vs Q3 2018−13.8% vs Q2 2019
Net Income-$26.61MN/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.40N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$27,119,000N/M
Operating Cash Flowderived-$19,838,000N/M
Free Cash Flowderived-$21,102,000N/M
Margins · derived
Operating margin-1116.5%+510.4 pt vs Q3 2018
Net margin-1095.5%+540.2 pt vs Q3 2018

What the release said

The release

Same quarter

MetricQ3 2019Q3 2018Q3 2017Q3 2016
Revenue$2.43M$1.03M$1.03M$1.03M
Net Income-$26.61M-$16.78M-$10.68M-$8.74M
EPS Diluted-$0.40-$0.31-$0.26-$0.27

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR